New 7 Tesla MRI research system ready for future clinical use

“I am extremely proud to announce the introduction of our new 7 Tesla scanner Magnetom Terra (1). It is the first 7 Tesla MRI scanner fully designed and manufactured by Siemens, with a completely new designed 7 Tesla magnet in its core”, said Dr. Bernd Ohnesorge, CEO Magnetic Resonance at Siemens Healthcare. “Now, Siemens is the only company to manufacture a complete human ultra-high field MRI system fully in-house.”

The Magnetom Terra 7 Tesla MRI system is designed to translate cutting-edge MRI research results into clinical application, and it is the world's first ultra-high field research system ready for future clinical use with planned CE and FDA authorization to market for selected neurological and musculoskeletal MR imaging applications.

The Dual Mode functionality allows users to switch from cutting-edge research modes to specific clinical protocols in less than ten minutes. The new 7 Tesla MRI system provides the whole range of cutting-edge 7 Tesla research functionalities, and is based on the latest software platform syngo MR E11, identical to Siemens' latest flagship 3 Tesla MRI systems, to enable consistent usability and protocol exchange.

Magnetom Terra's new actively shielded magnet is the lightest 7 Tesla whole body magnet in the world – 50 percent lighter than previous actively shielded 7 Tesla magnet generations. This is the result of a multi-year engineering project at Siemens Magnet Technologies in Oxford, capitalizing on the long-term experience of the team in the design and manufacturing of state-of-the-art 3 Tesla magnets for clinical use.

As a result, with Magnetom Terra, siting of a 7 Tesla MRI system becomes much easier and its location in a clinical environment becomes feasible. Combined with the Zero Helium boil-off technology, Magnetom Terra improves the lifecycle costs of ultra-high field MRI.

Magnetom Terra increases the potential for translating cutting-edge research capabilities into future clinical application – for anatomical, functional or metabolic MR imaging. This specially designed 7 Tesla technology makes this possible by offering:

• Up to eight channel parallel transmit technology for selective excitation and higher homogeneity in challenging body regions such as cardiac and abdominal.
• Up to 64 receive channels for higher coil density in the field of view to achieve higher acceleration factors, higher signal-to-noise ratio and higher spatial resolution, and a better coverage of the body regions of interest.
• High gradient strength of up to 80 millitesla per meter (mT/m) and a fast gradient switching rate of up to 200 Tesla per meter per second (T/m/s) for advanced studies with diffusion and functional MR imaging.
• The latest Siemens software platform syngo MR E11 identical to Siemens' latest flagship 3 Tesla MRI systems such as Magnetom Skyra and Magnetom Prisma.

For specific clinical areas, Magnetom Terra is prepared for future clinical use with planned CE and FDA authorization to market of the system and the corresponding local coils:

• Getting better insights into the musculoskeletal system through unprecedented high isotropic spatial resolution of 0.2 mm.
• Imaging brain tumors and irregularities in the brain's metabolic processes.
• Visualizing neurodegenerative diseases such as Alzheimer's disease, epilepsy, schizophrenia and multiple sclerosis.

“Based on our long-standing experience and the largest innovation network in human ultra-high field MRI, Siemens is committed to further grow the footprint of 7 Tesla MRI in research and clinical application”, explained Dr. Bernd Ohnesorge. “I am confident that our Magnetom Terra will help explore new territories in MRI research and at the same time it's the world's first 7 Tesla scanner designed for clinical use.”

This press release and press pictures are available at http://www.siemens.com/press/magnetom-terra

Further information can be found at: www.siemens.com/terra

1) Magnetom Terra is still under development and not commercially available yet. Its future availability cannot be ensured.

Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world's largest producers of energy-efficient, resource-saving technologies, Siemens is No. 1 in offshore wind turbine construction, a leading supplier of combined cycle turbines for power generation, a major provider of power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. The company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2014, which ended on September 30, 2014, Siemens generated revenue from continuing operations of €71.9 billion and net income of €5.5 billion. At the end of September 2014, the company had around 343,000 employees worldwide on a continuing basis.

Further information is available on the Internet www.siemens.com

Reference Number: PR2015060231HCEN

Contact

Mr. Thorsten Opderbeck
Healthcare
Siemens AG

Henkestr. 127

91052 Erlangen

Germany

Tel: +49 9131 84-4906

thorsten.opderbeck​@siemens.com